An interventional study of TENEO 317 Model 2 excimer laser in Myopia, sponsored by Bausch & Lomb Incorporated. Not yet recruiting. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Myopia by Bausch Health Companies Inc. — 3 open to participants now, 3 under way, none of them phase 3. Myopia · Bausch Health Companies Inc..
Among the 43 studies in Myopia by Bausch Health Companies Inc., this one is the 22nd largest by planned enrollment, is one of 2 that started in 2025, is one of 35 with no phase, and was the 42nd registered.
1,165 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →3 of the 43 studies in Myopia by Bausch Health Companies Inc. are open now, in 2 countries. Recruiting first, the newest first:
Bausch & Lomb GmbH · Sites in Czechia
Ages 18+
Bausch & Lomb Incorporated · Sites in China
Ages 8–12
By country, each count listing its studies:
Of the 123 Myopia studies recruiting now, 19 (15%) set no upper age limit and 103 (84%) stop at 75 or younger; 85 take children under 18; 52 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 140 is above the median of 79 across 928 interventional studies indexed under Myopia.
Median enrollment 140 across the 43 interventional studies. Of the 35 that completed or were terminated, 31 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
3 of the studies in Myopia by Bausch Health Companies Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06618547Bausch & Lomb IncorporatedEffectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy | 2026-11 |
| NCT06305663Bausch & Lomb IncorporatedA Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children | 2027-01-31 |
| NCT06997003Bausch & Lomb GmbHEvaluation of a New Laser Refractive Vision Correction Using the TENEO™ 317 Model 2 | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies in Myopia by Bausch Health Companies Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Study to Investigate the Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia with or without Astigmatism by Transepithelial Photorefractive Keratectomy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ocular conditions that may predispose the subject to future complications, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: TENEO 317 Model 2 excimer laser
TENEO 317 Model 2 excimer laser by Transepithelial Photorefractive Keratectomy
Maintenance of BCDVA -
lines lost \<5% of eyes with a loss of \>2 lines of BCDVA at the stability visit
Time frame: through study completion, an average of 1 year
Maintenance of BCDVA -
preservation 20/40 \<1% of eyes with a BCDVA of 20/20 or better preoperatively that have a BCDVA worse than 20/40 at the stability visit
Time frame: through study completion, an average of 1 year
Induced manifest refractive astigmatism
\<5% of eyes with induced manifest refractive astigmatism greater \>2 diopters at the stability visit
Time frame: through study completion, an average of 1 year
Induced manifest refractive astigmatism
\< 1% of eyes with serious adverse events by type of event observed through the final study visit.
Time frame: through study completion, an average of 1 year
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2025; primary completion for Nov 2026, 12 months later.
Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 12 months is above that.
Counting every sponsor, half of 437 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.